Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449845 | 0.83 | RAB9A (0.51) | TSHRSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL4447240 | 0.78 | HPGD (0.43) | TSHRSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL2440090 | 0.77 | HDAC6 (0.56) | TSHRSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL2710881 | 0.75 | RAB9A (0.51) | TSHRSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL2729058 | 0.72 | GSK3B (0.52) | TSHRSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL2727659 | 0.72 | TSHR (0.51) | TSHRSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL6714339 | 0.70 | MAPK8 (0.56) | LMNATDP2 | |
| SCHEMBL30489963 | 0.70 | MAPK8 (0.56) | LMNATDP2 | |
| SCHEMBL4703302 | 0.70 | CA2 (0.57) | CA2HTT | |
| SCHEMBL4256110 | 0.69 | HDAC6 (0.54) | TSHRSMN1; SMN2RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008127364-A2 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | TSHR 4811/4885SMN1; SMN2 1983/4885RAB9A 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.